A phase II study of Gleevec (imatinib mesylate, NSC 716051 formerly STI571) in children with refractory or relapsed solid tumors.
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2013
At a glance
- Drugs Imatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 19 Sep 2005 New trial record.